Literature DB >> 7866999

Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer.

M F Di Renzo1, R Poulsom, M Olivero, P M Comoglio, N R Lemoine.   

Abstract

The c-MET oncogene encodes the receptor for hepatocyte growth factor (HGF) scatter factor, a multifunctional cytokine able to mediate morphogenesis as well as invasive growth of epithelial cells. The c-MET-encoded receptor is detectable only at low levels in the normal human exocrine pancreas, but it is up-regulated in the majority of pancreatic ductal adenocarcinomas. The c-MET-encoded HGF receptor is also overexpressed in a proportion of the panel of 31 human pancreatic cancer cell lines examined, which have a range of different growth properties and degrees of differentiation. In most cases the HGF receptor found in the malignant cells has features of the normal receptor. When added to pancreatic cancer cell lines, HGF triggers receptor phosphorylation and stimulates cells to move and proliferate. In overexpressing cell lines, the Met/HGF receptor is phosphorylated in the absence of endogenously produced or exogenously added ligand. These data suggest that the Met/HGF receptor may be involved in the growth and behavior of pancreatic cancer and may contribute to the ductal phenotype of these tumors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7866999

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  71 in total

Review 1.  Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression.

Authors:  Alessia Locatelli; Kristopher A Lofgren; Andrea R Daniel; Nancy E Castro; Carol A Lange
Journal:  Horm Cancer       Date:  2012-04       Impact factor: 3.869

2.  An overview of the c-MET signaling pathway.

Authors:  Shawna Leslie Organ; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

Review 3.  Molecular mechanism of pancreatic cancer--understanding proliferation, invasion, and metastasis.

Authors:  André L Mihaljevic; Christoph W Michalski; Helmut Friess; Jörg Kleeff
Journal:  Langenbecks Arch Surg       Date:  2010-03-18       Impact factor: 3.445

4.  Phosphorylation of MUC1 by Met modulates interaction with p53 and MMP1 expression.

Authors:  Pankaj K Singh; Michelle E Behrens; John P Eggers; Ronald L Cerny; Jennifer M Bailey; Kandavel Shanmugam; Sandra J Gendler; Eric P Bennett; Michael A Hollingsworth
Journal:  J Biol Chem       Date:  2008-07-14       Impact factor: 5.157

Review 5.  Molecular biology of pancreatic cancer.

Authors:  Miroslav Zavoral; Petra Minarikova; Filip Zavada; Cyril Salek; Marek Minarik
Journal:  World J Gastroenterol       Date:  2011-06-28       Impact factor: 5.742

Review 6.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

7.  Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin.

Authors:  Véronique Orian-Rousseau; Helen Morrison; Alexandra Matzke; Thor Kastilan; Giuseppina Pace; Peter Herrlich; Helmut Ponta
Journal:  Mol Biol Cell       Date:  2006-10-25       Impact factor: 4.138

8.  NK1, a natural splice variant of hepatocyte growth factor/scatter factor, is a partial agonist in vivo.

Authors:  J L Jakubczak; W J LaRochelle; G Merlino
Journal:  Mol Cell Biol       Date:  1998-03       Impact factor: 4.272

9.  Integrin α6β4 Promotes Autocrine Epidermal Growth Factor Receptor (EGFR) Signaling to Stimulate Migration and Invasion toward Hepatocyte Growth Factor (HGF).

Authors:  Brittany L Carpenter; Min Chen; Teresa Knifley; Kelley A Davis; Susan M W Harrison; Rachel L Stewart; Kathleen L O'Connor
Journal:  J Biol Chem       Date:  2015-09-17       Impact factor: 5.157

10.  Phenotypic switch from paracrine to autocrine role of hepatocyte growth factor in an androgen-independent human prostatic carcinoma cell line, CWR22R.

Authors:  Koh-Ichi Nakashiro; Shingo Hara; Yuji Shinohara; Miho Oyasu; Hitoshi Kawamata; Satoru Shintani; Hiroyuki Hamakawa; Ryoichi Oyasu
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.